BPC-157 Side Effects: What the Published Research Shows

The most directly relevant toxicology dataset is a 2020 study published in Regulatory Toxicology and Pharmacology, which tested BPC-157 in mice, rats, rabbits and dogs across single-dose and repeated-dose designs, plus dedicated local-tolerance, genetic-toxicity and embryo-fetal-toxicity testing. The single-dose toxicity study, run up to 20 mg/kg in rats, found no test-related effects the researchers could attribute to BPC-157, and no lethal dose was identified.^[1]

Repeated dosing in dogs was well tolerated overall. The one change outside the control range was a decrease in creatinine, a standard kidney-function marker, at the highest repeated dose tested of 2 mg/kg; lower doses showed no such change, and the treated dogs' creatinine recovered spontaneously within two weeks after dosing stopped. The study's local-tolerance testing found only mild irritation at the injection site, and neither genetic toxicity nor embryo-fetal toxicity was observed.^[1]

That is, as far as the published literature reaches, the single most concrete adverse finding anywhere in the BPC-157 safety record: one reversible laboratory change, in dogs, at the highest repeated dose tested. The researchers framed the overall dataset as supporting further clinical development, not as a safety concern.^[1]

Human evidence is far thinner than the animal record. A 2025 narrative review in Current Reviews in Musculoskeletal Medicine could identify only three published human studies of BPC-157, and all three were small, uncontrolled pilot studies rather than dedicated safety trials. The largest, a 2021 retrospective study that contacted 16 patients who had received intra-articular BPC-157 knee injections about their pain relief 6 months to a year later, did not report adverse effects, but the review notes that adverse-event screening in that study "was not discussed at length".^[3]

A 2024 pilot study gave 12 patients with interstitial cystitis intravesicular (bladder) BPC-157 and specifically screened for fever, skin rash, nausea, vomiting, worsening urinary symptoms and pain during intercourse; none of the 12 participants reported any of those effects. The most directly safety-focused study is a 2025 pilot trial that gave intravenous BPC-157 to two healthy adult volunteers and tracked them afterward; it reported no adverse effects, with plasma levels back to baseline within 24 hours.^[3][2]

Two volunteers and two small outpatient pilots are not a safety database. The review's own caution is worth repeating directly: every published human study of BPC-157 to date has reported a favourable outcome, which its authors flag as a possible sign of publication bias, concluding that BPC-157 "should be considered investigational, and its use approached with caution" until well-designed clinical trials exist.^[3]

Beyond what has actually been observed, researchers have flagged theoretical concerns based on BPC-157's own proposed mechanism of action, not on any adverse event recorded in an animal or human study. The 2025 review lists three: pathological (disease-driving) blood-vessel growth, formation of toxic metabolites, and overproduction of nitric oxide.^[3]

The most-discussed of these is the angiogenesis question. BPC-157's research interest rests partly on its ability to promote new blood-vessel growth through VEGFR-2 signalling, the same pathway implicated in tumour growth and in some inflammatory diseases. No published study has reported an increased tumour rate or any other cancer-related outcome from BPC-157 research; the concern in the literature is mechanistic reasoning, not an observed result.^[3]

It matters that these two evidence types do not contradict each other so much as sit at different stages: the dedicated toxicology study found no genetic toxicity and no tumour-related findings in its animal testing, while the review's caution is about what has not yet been tested for, specifically longer-duration human exposure at scale. Neither is a documented case of BPC-157 causing cancer; both are honest statements about the limits of what has been checked.^[1][3]

BPC-157 sits in FDA's Category 2 of nominated bulk drug substances, the category FDA uses for substances where its review identified potential significant safety risks in the compounding context. That is a regulatory categorisation, not a toxicology finding, and it does not contradict the preclinical safety data described above; it reflects how little human-dosing history and quality-control data exists for the substance outside formal trials.^[4]

The World Anti-Doping Agency separately added BPC-157 to its Prohibited List in 2022, under section S0 (Non-Approved Substances), the category for pharmacological substances with no current approval for human therapeutic use by any government health authority. Reviewers connect both the FDA and WADA positions to the same underlying gap: an unregulated, widely available research compound with an unknown human-toxicity profile at scale, not a specific documented harm.^[5][3]

Peptyds' complete BPC-157 guide covers this regulatory picture in full, including the EMA's non-authorisation and how the FDA's compounding caution is worded. This article's scope stays on the safety data itself; read the full guide for the regulatory detail.

The two peptides are frequently discussed together, and the comparison question comes up often enough to answer directly: BPC-157 and TB-500 (a synthetic fragment of thymosin beta-4) do not share a published safety dataset. The 2021 knee-injection study mentioned above did test BPC-157 combined with thymosin beta-4 in some patients, but as a pain-relief comparison, not as a safety study of the combination.^[3]

The only controlled human safety data anywhere near this topic comes from a 2021 phase 1 trial of full-length recombinant thymosin beta-4, a larger, related but distinct molecule, not the shorter TB-500 fragment sold as a research peptide. In that trial's multiple-dose arm, mild-to-moderate adverse events occurred about as often with thymosin beta-4 as with placebo, and no serious adverse events or dose-limiting toxicity were reported.^[6]

No published controlled human trial has tested the TB-500 fragment itself. So the honest answer to "do BPC-157 and TB-500 have side effects" is that BPC-157 has the animal-toxicology and small-pilot picture described above, thymosin beta-4 (the full-length parent molecule) has one reassuring phase 1 trial, and TB-500 specifically has no published human safety trial at all.^[3][6]